Summary
The purpose of the study is to evaluate the safety and tolerability of pepinemab in
combination with pembrolizumab as first-line treatment and determine a recommended Phase 2
dose (RP2D) in patients with recurrent or metastatic head and neck squamous cell carcinoma
(R/M HNSCC).